ZYNE Stock Chart

Zynerba Pharmaceuticals develops next-generation synthetic cannabinoid therapeutics for transdermal delivery for patients with high unmet medical needs.
The Company's mission is to improve the lives of patients battling severe health conditions including epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain through these therapeutics.
Its development pipeline includes patent-protected synthetic transdermal cannabinoid products, which Zynerba believes will provide new treatment options for patients as well as additional treatment options for patients not currently receiving adequate relief or otherwise experiencing intolerable side effects from current treatment regimes.